Eun Bong Lee

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text

Medicine, Immunology, Pharmacology +13

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Eun Bong Lee, Roy Fleischmann, Stephen Hall et al. · New England Journal of Medicine · 2014 · 774 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Stanley Cohen, Yoshiya Tanaka, Xavier Mariette et al. · Annals of the Rheumatic Diseases · 2017 · 395 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese et al. · Arthritis & Rheumatism · 2011 · 379 citations

Medicine, Pharmacology, Pharmacotherapy +15

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14